oxonic acid has been researched along with Eye Disorders in 5 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 mg/kg/day regimen produced one dead or moribund dog of each sex; black-brown patch (melanin deposition) and inflammatory changes in the eyes and skin; decreased in body weight gains; increases in MCV, MCH, monocyte ratio, and serum protein and uric acid; decreases in lymphocyte ratio and erythrocyte count, hematocrit, hemoglobin, albumin, A/G ratio, cholesterol (esterified, total and free), phospholipids, triglycerides, cholinesterase activity and creatinine; increases in relative liver and adrenal weights." | 3.69 | [A 52-week oral toxicity study of a new antineoplastic agent S-1 in dogs]. ( Enomoto, M; Inoue, H; Kitajima, S; Kobayashi, K; Okamura, T; Watari, N; Yamaguchi, S, 1996) |
| "Eye disorders are one of the characteristic adverse events associated with S-1 chemotherapy." | 1.43 | [Eye Disorders Associated with S-1 Chemotherapy in Gastric Cancer Patients]. ( Fujii, C; Fujita, J; Hayashi, H; Ishizaka, T; Kamigaki, S; Kimura, Y; Makari, Y; Mikami, J; Yanagishita, Y; Yasui, Y, 2016) |
| "When epiphora is observed in patients on S-1 therapy, it is necessary to assess optic disorders by an opthalmologist immediately because of suspicion of injury to the cornea and lacrimal duct." | 1.36 | [Optic lesions in patients with epiphora during S-1 therapy]. ( Atsumi, H; Kuze, S; Kyokane, T; Nakamura, H; Shibahara, H; Takamizawa, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moriya, K | 1 |
| Shimizu, H | 1 |
| Handa, S | 1 |
| Sasaki, T | 1 |
| Sasaki, Y | 1 |
| Takahashi, H | 1 |
| Nakamura, S | 1 |
| Yoshida, H | 1 |
| Kato, Y | 1 |
| Fujii, C | 1 |
| Kimura, Y | 1 |
| Makari, Y | 1 |
| Mikami, J | 1 |
| Fujita, J | 1 |
| Kamigaki, S | 1 |
| Hayashi, H | 1 |
| Yanagishita, Y | 1 |
| Yasui, Y | 1 |
| Ishizaka, T | 1 |
| Chikama, T | 1 |
| Takahashi, N | 1 |
| Wakuta, M | 1 |
| Nishida, T | 1 |
| Shibahara, H | 1 |
| Kuze, S | 1 |
| Kyokane, T | 1 |
| Takamizawa, J | 1 |
| Nakamura, H | 1 |
| Atsumi, H | 1 |
| Kitajima, S | 1 |
| Okamura, T | 1 |
| Kobayashi, K | 1 |
| Watari, N | 1 |
| Inoue, H | 1 |
| Enomoto, M | 1 |
| Yamaguchi, S | 1 |
5 other studies available for oxonic acid and Eye Disorders
| Article | Year |
|---|---|
Incidence of Ophthalmic Disorders in Patients Treated with the Antineoplastic Agent S-1.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Eye Diseases; Female; Humans; Incidence; M | 2017 |
[Eye Disorders Associated with S-1 Chemotherapy in Gastric Cancer Patients].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Eye Diseases; Fe | 2016 |
Noninvasive direct detection of ocular mucositis by in vivo confocal microscopy in patients treated with S-1.
Topics: Aged; Antineoplastic Agents; Drug Combinations; Eye Diseases; Female; Humans; Inflammation; Male; Mi | 2009 |
[Optic lesions in patients with epiphora during S-1 therapy].
Topics: Adult; Aged; Aged, 80 and over; Drug Combinations; Eye Diseases; Female; Humans; Lacrimal Apparatus | 2010 |
[A 52-week oral toxicity study of a new antineoplastic agent S-1 in dogs].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Chemical Analysis; Blood Coagu | 1996 |